GW rises as Epidiolex passes second Phase III test

GW Pharmaceuticals plc (LSE:GWP; NASDAQ:GWPH) said anticonvulsive therapy Epidiolex cannabidiol significantly reduced the monthly frequency of drop seizures in patients with Lennox-Gastaut syndrome (LGS), meeting the primary

Read the full 270 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE